Literature DB >> 32206132

Isolated Hepatic Metastasis of Prostate Cancer with Variable 18F-fluociclovine Uptake by PET/CT Imaging.

Endel Sorra1, Muhammad U Aziz1, Fangyu Peng1,2,3.   

Abstract

A 74-year-old man presented with rapid rising prostate-specific antigen (PSA) 2 years after treatment of prostate cancer with prostatectomy and salvage radiation therapy. PSA increased from 923 to 4349 ng/mL within 2 months. No osseous metastatic lesions of prostate cancer were detected by 18F-sodium fluoride PET/CT imaging at an outside facility. 18F-fluciclovine PET/CT imaging was performed to evaluate local recurrence of prostate cancer at surgical bed of prostatectomy and distant metastasis. One small focus of low-level 18F-fluciclovine radiotracer uptake was noted in the surgical bed of prostatectomy without corresponding soft tissue mass on CT. No fluciclovine-avid lymph nodes or osseous metastatic lesions were detected, but multiple hypodense lesions of variable 18F-fluciclovine radiotracer uptake were noted in the liver, concerning for isolated liver metastasis of prostate cancer. The patient underwent docetaxel chemotherapy for treatment of prostate cancer liver metastasis and showed a favorable response to treatment by significant decreased size of the hypodense lesions in the liver on post treatment abdominal CT, along with dramatic reduction of PSA level and improvement of liver function. The findings from this case highlight the importance of checking hypoattenuating lesions in the liver for the presence of prostate cancer metastatic lesions that might appear similar to other benign hypoattenuating lesions of low fluciclovine uptake relative to physiological 18F-fluciclovine uptake in the normal liver tissues, a potential pitfall at interpretation of 18F-fluociclovine PET/CT imaging. © Korean Society of Nuclear Medicine 2019.

Entities:  

Keywords:  18F-fluociclovine PET/CT; Liver metastasis; Prostate cancer

Year:  2019        PMID: 32206132      PMCID: PMC7062979          DOI: 10.1007/s13139-019-00623-9

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  16 in total

1.  A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer.

Authors:  Shuntaro Oka; Ryota Hattori; Fumie Kurosaki; Masahito Toyama; Larry A Williams; Weiping Yu; John R Votaw; Yasunori Yoshida; Mark M Goodman; Osamu Ito
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

2.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

Authors:  David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

3.  Intrahepatic portal hypertension secondary to metastatic carcinoma of the prostate.

Authors:  Tan Attila; Milton W Datta; Gary Sudakoff; Majed Abu-Hajir; Benson T Massey
Journal:  WMJ       Date:  2007-02

4.  Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti; Shuntaro Oka; Hiroyuki Okudaira; Yusuke Inoue; Jens Sörensen; Rikard Owenius; Peter Choyke; Baris Turkbey; Trond V Bogsrud; Tore Bach-Gansmo; Raghuveer K Halkar; Jonathon A Nye; Oluwaseun A Odewole; Bital Savir-Baruch; Mark M Goodman
Journal:  J Nucl Med       Date:  2014-11-13       Impact factor: 10.057

5.  ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer.

Authors:  Bital Savir-Baruch; Kevin P Banks; Jonathan E McConathy; Olga P Molchanova-Cook; Ephraim E Parent; Amol Takalkar; Mark Tulchinsky; Jian Q Yu; Rathan M Subramaniam; David M Schuster
Journal:  Clin Nucl Med       Date:  2018-12       Impact factor: 7.794

Review 6.  Radiolabeled amino acids: basic aspects and clinical applications in oncology.

Authors:  P L Jager; W Vaalburg; J Pruim; E G de Vries; K J Langen; D A Piers
Journal:  J Nucl Med       Date:  2001-03       Impact factor: 10.057

Review 7.  Review of 18F-Fluciclovine PET for Detection of Recurrent Prostate Cancer.

Authors:  Mariya Gusman; Jamie A Aminsharifi; Justin G Peacock; Shane B Anderson; Michael N Clemenshaw; Kevin P Banks
Journal:  Radiographics       Date:  2019 May-Jun       Impact factor: 5.333

8.  L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer.

Authors:  Takeshi Sakata; Golam Ferdous; Tomoko Tsuruta; Takefumi Satoh; Shiro Baba; Tomoko Muto; Akinori Ueno; Yoshikatsu Kanai; Hitoshi Endou; Isao Okayasu
Journal:  Pathol Int       Date:  2009-01       Impact factor: 2.534

9.  Successful resection of a solitary metastatic liver tumor from prostate cancer 15 years after radical prostatectomy: a case report.

Authors:  Hironari Kawai; Hiroaki Shiba; Masaru Kanehira; Taro Sakamoto; Kenei Furukawa; Katsuhiko Yanaga
Journal:  Surg Case Rep       Date:  2017-01-25

10.  Liver Metastases in Prostate Carcinoma Represent a Relatively Aggressive Subtype Refractory to Hormonal Therapy and Short-Duration Response to Docetaxel Monotherapy.

Authors:  Arsh Singh; Naga K S Cheedella; Shams A Shakil; Frederick Gulmi; Dong-Sung Kim; Jen C Wang
Journal:  World J Oncol       Date:  2015-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.